Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ADAPTIVE BIOTECHNOLOGIES CORPORATION

(ADPT)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
12/01/2021 12/02/2021 12/03/2021 12/06/2021 12/07/2021 Date
25.19(c) 26.23(c) 25.36(c) 25.17(c) 27.63(c) Last
855 331 736 435 1 543 467 873 122 843 422 Volume
-3.45% +4.13% -3.32% -0.75% +9.77% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 153 M - -
Net income 2021 -211 M - -
Net cash position 2021 273 M - -
P/E ratio 2021 -18,5x
Yield 2021 -
Sales 2022 197 M - -
Net income 2022 -241 M - -
Net cash position 2022 106 M - -
P/E ratio 2022 -16,5x
Yield 2022 -
Capitalization 3 899 M 3 899 M -
EV / Sales 2021 23,7x
EV / Sales 2022 19,3x
Nbr of Employees 622
Free-Float 98,5%
More Financials
Company
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company is focused on using the biology of the adaptive immune system to develop the diagnosis and treatment of disease. Its immune medicine platform combines a suite of chemistry, biology and machine learning to generate clinical immunomics data to decode the adaptive immune system. Its commercial research products include immunoSEQ and... 
Sector
Biotechnology & Medical Research
Calendar
12/11 | 05:30pmPresentation
More about the company
Ratings of Adaptive Biotechnologies Corporation
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C
More Ratings
All news about ADAPTIVE BIOTECHNOLOGIES CORPORATION
12/02Adaptive Biotechnologies and Collaborators to Present More than 30 Abstracts on Utility..
AQ
12/02Adaptive Biotechnologies Corporation Present More than 30 Abstracts on Utility of clono..
CI
11/11Adaptive Biotechnologies Receives Updated Medicare Coverage for its Minimal Residual Di..
GL
11/11Adaptive Biotechnologies Receives Updated Medicare Coverage for its Minimal Residual Di..
GL
11/11Adaptive Biotechnologies Receives Updated Medicare Coverage for its Minimal Residual Di..
CI
11/03Adaptive Biotechnologies Q3 2021 Earnings Presentation
PU
11/03ADAPTIVE BIOTECHNOLOGIES : Q3 Earnings Snapshot
AQ
11/03Adaptive Biotechnologies Reports Narrower-Than-Expected Loss, Revenue Tops Estimates
MT
11/03Adaptive Biotechnologies Reports Third Quarter 2021 Financial Results - Form 8-K
PU
11/03ADAPTIVE BIOTECHNOLOGIES CORP Management's Discussion and Analysis of Financial Condit..
AQ
11/03Adaptive Biotechnologies Corporation Reports Earnings Results for the Third Quarter and..
CI
11/03ADAPTIVE BIOTECHNOLOGIES CORP : Results of Operations and Financial Condition, Change in D..
AQ
11/03Adaptive Biotechnologies Corporation Designates Kyle Piskel as the Company's Principal ..
CI
11/03Earnings Flash (ADPT) ADAPTIVE BIOTECHNOLOGIES Posts Q3 Revenue $39.5M, vs. Street Est ..
MT
11/03Adaptive Biotechnologies Reports Third Quarter 2021 Financial Results
GL
More news
News in other languages on ADAPTIVE BIOTECHNOLOGIES CORPORATION
11/03Adaptive Biotechnologies enregistre une perte plus étroite que prévu, mais son chiffre ..
11/03Earnings Flash (ADPT) ADAPTIVE BIOTECHNOLOGIES affiche un chiffre d'affaires de 39,5 mi..
11/03Adaptive Biotechnologies réitère ses prévisions de revenus pour l'ensemble de l'année 2..
08/05Adaptive Biotechnologies nomme un responsable commercial en chef
08/04Earnings Flash (ADPT) ADAPTIVE BIOTECHNOLOGIES annonce un chiffre d'affaires de 38,5 mi..
More news
Analyst Recommendations on ADAPTIVE BIOTECHNOLOGIES CORPORATION
More recommendations
Chart ADAPTIVE BIOTECHNOLOGIES CORPORATION
Duration : Period :
Adaptive Biotechnologies Corporation Technical Analysis Chart | ADPT | US00650F1093 | MarketScreener
Technical analysis trends ADAPTIVE BIOTECHNOLOGIES CORPORATION
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 27,63 $
Average target price 56,00 $
Spread / Average Target 103%
EPS Revisions
Managers and Directors
Chad Robins Chairman & Chief Executive Officer
Julie Rubinstein President
Chad M. Cohen Chief Financial Officer
Harlan Robins Chief Scientific Officer
Lance Baldo Chief Medical Officer
Sector and Competitors